INT48792

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1994
Last Reported 2011
Negated 2
Speculated 1
Reported most in Body
Documents 48
Total Number 50
Disease Relevance 36.56
Pain Relevance 1.80

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (ERBB2) signal transduction (ERBB2) plasma membrane (ERBB2)
nucleus (ERBB2) cytoplasm (ERBB2)
Anatomy Link Frequency
blood 1
lymph node 1
liver 1
arm 1
T cells 1
ERBB2 (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 202 100.00 Very High Very High Very High
addiction 37 99.60 Very High Very High Very High
Pain 32 96.24 Very High Very High Very High
Neuropathic pain 4 94.88 High High
depression 10 94.16 High High
Chronic pancreatitis 1 91.60 High High
metalloproteinase 4 89.92 High High
Multiple sclerosis 9 85.32 High High
palliative 17 83.92 Quite High
COX2 2 83.92 Quite High
Disease Link Frequency Relevance Heat
Cancer 1917 100.00 Very High Very High Very High
INFLAMMATION 189 100.00 Very High Very High Very High
Ovarian Cancer 116 99.84 Very High Very High Very High
Liver Disease 4 99.84 Very High Very High Very High
Aneuploidy 13 99.74 Very High Very High Very High
Inflammatory Breast Neoplasms 145 99.66 Very High Very High Very High
Carcinoma 107 99.28 Very High Very High Very High
Adenocarcinoma 39 99.16 Very High Very High Very High
Breast Cancer 1246 99.00 Very High Very High Very High
Apoptosis 219 99.00 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In cases where the Her2 pathway is deregulated, carcinogenesis results.


Regulation (deregulated) of Her2
1) Confidence 0.57 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721347 Disease Relevance 0.29 Pain Relevance 0
A Cox regression model including also age, sex, tumor stage, and histology as covariates confirmed the role of HER-2 transcript ratio as main factor (P = .012) affecting the patients' survival, whereas other covariates showed no effect.
Regulation (role) of HER-2 associated with cancer
2) Confidence 0.44 Published 2010 Journal Journal of Nucleic Acids Section Body Doc Link PMC2911612 Disease Relevance 0.47 Pain Relevance 0
GB, MDB, MPC, FF, FLV and MS were responsible of pathologic assessment and HER2 testing.
Regulation (responsible) of HER2
3) Confidence 0.43 Published 2007 Journal BMC Cancer Section Body Doc Link PMC1832208 Disease Relevance 0.30 Pain Relevance 0
SMRT array CGH, in addition to detecting the ERBB2 locus, revealed several additional discrete changes on the 17q arm in these cell lines.
Regulation (detecting) of ERBB2 in arm
4) Confidence 0.43 Published 2006 Journal Breast Cancer Res Section Body Doc Link PMC1413994 Disease Relevance 0 Pain Relevance 0
Letrozole was equally effective for HER1/HER2+ and HER1/HER2?
Regulation (effective) of HER1/HER2
5) Confidence 0.43 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001223 Disease Relevance 0.46 Pain Relevance 0
Letrozole was equally effective for HER1/HER2+ and HER1/HER2?
Regulation (effective) of HER1/HER2
6) Confidence 0.43 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001223 Disease Relevance 0.46 Pain Relevance 0
Our results demonstrate that local therapy with scFv(FRP5)-ETA can be effective against ErbB2 expressing tumors justifying further clinical development of this reagent.
Regulation (effective) of ErbB2 associated with cancer
7) Confidence 0.43 Published 2003 Journal Breast Cancer Res. Treat. Section Abstract Doc Link 14703062 Disease Relevance 1.00 Pain Relevance 0.13
Recent evidence has suggested that HER2+ tumors can continue to proliferate despite neoadjuvant letrozole or tamoxifen treatment, which could imply therapeutic resistance that may manifest later in the clinical course of the disease [96].
Regulation (continue) of HER2 associated with cancer and disease
8) Confidence 0.42 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001217 Disease Relevance 0.59 Pain Relevance 0
Although lapatinib targets both EGFR and HER2, its effects on HER2 appear to be more critical.
Regulation (effects) of HER2
9) Confidence 0.42 Published 2010 Journal Cancer management and research Section Abstract Doc Link PMC3004582 Disease Relevance 0.93 Pain Relevance 0
Trastuzumab is a recombinant, humanized monoclonal antibody (rhMab4D5), targeting the extracellular domain of Her2 (human EGFR related), also known as erbB2 or neu (Hynes and Stern 1994; Nahta et al 2006).
Regulation (targeting) of Her2
10) Confidence 0.42 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721347 Disease Relevance 0.53 Pain Relevance 0
Twelve genes were deregulated in ERBB2-amplified IBCs.
Regulation (deregulated) of ERBB2
11) Confidence 0.41 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958950 Disease Relevance 0.78 Pain Relevance 0.14
Chromosomal regions altered by CNAs in NIBC and IBC ERBB2-amplified tumors
Regulation (altered) of ERBB2 associated with inflammation and cancer
12) Confidence 0.41 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958950 Disease Relevance 1.26 Pain Relevance 0.27
0.5|) genes with a frequency different in ER- and ER+ ERBB2-amplified BCs (Fisher exact test p ?
Regulation (different) of ERBB2
13) Confidence 0.41 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958950 Disease Relevance 0.09 Pain Relevance 0
Neratinib and trastuzumab exert their effect on the HER2 receptor at various molecular sites, and it has been suggested that the combination of both agents may be synergistic.
Regulation (effect) of HER2 receptor
14) Confidence 0.41 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2972555 Disease Relevance 1.41 Pain Relevance 0
Pertuzumab inhibits the formation of the HER2 heterodimer, independent of HER2 expression levels, and its binding site does not overlap with the epitope on HER2 that is recognized by trastuzumab (Herceptin) (14,15).
Neg (independent) Regulation (independent) of HER2
15) Confidence 0.39 Published 2009 Journal Japanese Journal of Clinical Oncology Section Body Doc Link PMC2661001 Disease Relevance 0.89 Pain Relevance 0.15
g/ml trastuzumab, did not have a significant effect on HER2 expression level or activity.
Regulation (effect) of HER2
16) Confidence 0.29 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2949655 Disease Relevance 0.33 Pain Relevance 0
M had no effect on HER2 expression level or the degree of phosphorylation, and, when added to 1 ?
Neg (no) Regulation (effect) of HER2
17) Confidence 0.29 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2949655 Disease Relevance 0.41 Pain Relevance 0
In this review, we provide an overview of recent developments in HER2 testing and results of clinical trials targeting HER2 in gastroesophageal adenocarcinoma.
Regulation (targeting) of HER2 associated with adenocarcinoma
18) Confidence 0.27 Published 2011 Journal Pathology Research International Section Abstract Doc Link PMC3005843 Disease Relevance 0.46 Pain Relevance 0
The aim of this paper is to provide an overview of recent developments in HER2 testing and results of clinical trials targeting HER2 in gastric and esophageal adenocarcinoma.
Regulation (targeting) of HER2 associated with adenocarcinoma
19) Confidence 0.27 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 1.10 Pain Relevance 0.08
Limited histopathologic analyses have shown that some such tumors exhibit significant HER2/neu immunoreactivity, suggesting a potential role for HER2-based therapy.
Regulation (immunoreactivity) of HER2/neu associated with cancer
20) Confidence 0.26 Published 2010 Journal Head Neck Oncol Section Abstract Doc Link PMC2889991 Disease Relevance 0.99 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox